Application of an iPSC‐Derived Organoid Model for Localized Scleroderma Therapy (Adv. Sci. 16/2022)

Localized Scleroderma Therapy Human‐induced pluripotent stem cell (hiPSC)‐derived epithelial and mesenchymal (EM) organoids can be used to investigate the therapeutic potential for the recovery of localized scleroderma (LoS) associated phenotypes and skin‐associated functions. In article number 2106...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jie, Li, Wei, Cao, Ruiyuan, Gao, Dunqin, Zhang, Qiyu, Li, Xiao, Li, Biyou, Lv, Luye, Li, Mansheng, Jiang, Junyi, Wang, Yujie, Li, Jun, Wu, Zhihong, Zhu, Yunping, Zhong, Wu, Zhang, Shuyang, Leng, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Inside Back Cover
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165512/
http://dx.doi.org/10.1002/advs.202270104
Descripción
Sumario:Localized Scleroderma Therapy Human‐induced pluripotent stem cell (hiPSC)‐derived epithelial and mesenchymal (EM) organoids can be used to investigate the therapeutic potential for the recovery of localized scleroderma (LoS) associated phenotypes and skin‐associated functions. In article number 2106075, Wu Zhong, Shuyang Zhang, Ling Leng, and co‐workers, establish an experimental EM organoid model from hiPSC to significantly reduce the degree of skin fibrosis and inflammation. Most importantly, it promotes the regeneration of epidermis and their appendages, providing a new therapeutic alternative for patients suffering from disfigurement and skin function defects caused by LoS. [Image: see text]

Ejemplares similares